ArticleClinical and translational medicine2022

Genome-wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes.

Qianqian Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.